Loading...

CNTX CONTEXT THERAPEUTICS INC Company Mergers 8-K Filing

CNTX

CNTX

CONTEXT THERAPEUTICS INC

(CNTX)

2026 8-K

License Agreement Update

Court Approval Announcement

FDA Fast Track Approval

Corporate Presentation Update

Court Ruling Update

Judicial Agreement Filed

Corporate Presentation Update

Q3 Results Update

Stock Sale Update

Nasdaq Extension Granted

Reverse Stock Split

Investor Meetings

Clinical Trial Update

Nasdaq Notification

Clinical Trial Update

License Agreement

Board Appointments

Annual Meeting of Stockholders

Private Placement

FDA IND Application Submission

Bylaws Amendment

Amendment of Collaboration ...

Press Release and Corporate...

Regulation FD Disclosure

Compliance with Minimum Bid...

Annual Meeting of Stockholders

Financial Results and Disco...

Regulation FD Disclosure

Press Release and Corporate...

External Links:

On May 14, 2026, Context Therapeutics amended its license agreement with BioAtla, agreeing to pay $4.5 million immediately and an additional $2.0 million by August 1, 2026, while securing irrevocable rights to develop certain antibody assets without future royalty obligations.

AI Assistant

CONTEXT THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.